Early Ga-68 FAPI PET/MR After Acute Myocardial Infarction

NCT07684924 · tracked via the Priya Life Science Turkey tracker

Sponsor

Ankara University

Phase

Observational

Started

2026-07-01

Last updated

2026-07-27

Condition(s) studied

Acute Myocardial Infarction (AMI)

Investigational drug(s) / intervention(s)

68Ga-FAPI-04 PET/MR

68Ga-FAPI-04 PET/MR: Hybrid 68Ga-FAPI PET/MR performed to evaluate myocardial fibroblast activation following acute myocardial infarction. PET and MR imaging findings will be analyzed in relation to infarct characteristics, myocardial function, and clinical outcomes.

Study summary

Acute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling and impaired cardiac function. Fibroblast activation protein (FAP)-targeted positron emission tomography (PET) enables noninvasive visualization of activated fibroblasts and may provide an early imaging biomarker of myocardial remodeling. This prospective single-center observational study aims to evaluate myocardial fibroblast activation using Ga-68 FAPI PET/MR performed approximately 10 ± 2 days after AMI and to investigate its association with subsequent left ventricular remodeling. Serial cardiac magnetic resonance (CMR) examinations will be performed at 3 and 6 months to assess changes in ventricular function and remodeling. The study will investigate whether early myocardial FAPI uptake is associated with subsequent structural and functional changes detected by CMR and evaluate the potential role of Ga-68 FAPI PET/MR as an imaging biomarker for post-infarction remodeling.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * Age ≥18 years. * Diagnosis of acute myocardial infarction according to current guideline criteria. * Successful coronary revascularization when clinically indicated. * Ability to undergo FAPI PET/MR. * Written informed consent. Exclusion Criteria: * Contraindications to MRI (e.g., non-MR-compatible implanted devices, severe claustrophobia). * Pregnancy or breastfeeding. * Severe renal impairment precluding gadolinium administration (if contrast-enhanced MR is performed). * Inability to provide informed consent. * Any condition considered by the investigator to interfere with study participation.

Primary outcome measure(s)

Left Ventricular Remodeling Assessed by Cardiac Magnetic Resonance Imaging — 6 months
Association between early myocardial Ga-68 FAPI uptake and left ventricular remodeling assessed by serial cardiac magnetic resonance imaging using changes in left ventricular volumes and systolic function.

Trial sites (1)

Facility	City	Region	Status
Ankara University Faculty of Medicine, Department of Nuclear Medicine	Ankara	Turkey (Türkiye)	Recruiting

More Ankara University trials in Turkey

Volume-Stable Collagen Matrix vs. Connective Tissue Graft for Peri-Implant Soft Tissue Defects Recruiting

Does Early Postoperative Fluid Management Affect Functional Delayed Graft Function After Living Donor Kidney Transplantation? Active, not recruiting

Comparison of Holmium, Thulium:YAG, and Thulium Fiber Lasers in Prostate Enucleation Starting soon

Effects of Reflexology and Cold Application Before Chest Tube Removal in CABG Patients Recruiting

The Effect of Virtual Reality Glasses on Pain Perception Enrolling by invitation

Other trials for the same condition

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Active, not recruiting

Machine Learning for Diagnosis of Occlusive MI in LBBB Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07684924 on ClinicalTrials.gov ↗ ← All trials in Turkey